Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention Trials.

ABSTRACT: Demonstrating a slowing in the rate of cognitive decline is a common outcome measure in clinical trials in Alzheimer's disease (AD). Selection of cognitive endpoints typically includes modeling candidate outcome measures in the many, richly phenotyped observational cohort studies available. An important part of choosing cognitive endpoints is a consideration of improvements in performance due to repeated cognitive testing (termed "practice effects"). As primary and secondary AD prevention trials are comprised predominantly of cognitively unimpaired participants, practice effects may be substantial and may have considerable impact on detecting cognitive change. The extent to which practice effects in AD prevention trials are similar to those from observational studies and how these potentia

SUBMITTER: Aschenbrenner AJ 

PROVIDER: S-EPMC9244171 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature